Whalen Carol K, Jamner Larry D, Henker Barbara, Gehricke Jena-Guido, King Pamela S
Department of Psychology and Social Behavior, University of California, Irvine, CA, USA.
Psychol Addict Behav. 2003 Dec;17(4):332-5. doi: 10.1037/0893-164X.17.4.332.
There is continuing concern that pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) may raise the risk of smoking (the gateway hypothesis). Alternatively, unmedicated people with ADHD may use nicotine to improve attentional and self-regulatory competence (the self-medication hypothesis). From a community sample of 511 adolescents participating in a longitudinal health study, 27 were identified as having ADHD, and 11 of these were receiving pharmacotherapy. Self-report surveys, electronic diaries, and salivary cotinine all indicated that adolescents treated with pharmacotherapy for ADHD smoked less than their untreated counterparts over 2 years of high school. These convergent findings from 3 disparate indicators lend support to the self-medication hypothesis over the gateway hypothesis, although alternative explanations need further study. The findings also suggest that early treatment of psychological and behavioral problems may prevent or delay smoking initiation.
人们一直担心注意力缺陷多动障碍(ADHD)的药物治疗可能会增加吸烟风险(即“入门假说”)。另一种观点认为,未接受药物治疗的ADHD患者可能会使用尼古丁来提高注意力和自我调节能力(即“自我药物治疗假说”)。在参与一项纵向健康研究的511名青少年社区样本中,有27人被确定患有ADHD,其中11人正在接受药物治疗。自我报告调查、电子日记和唾液可替宁检测均表明,在高中的两年时间里,接受ADHD药物治疗的青少年比未接受治疗的青少年吸烟更少。来自3个不同指标的这些一致发现支持了自我药物治疗假说而非入门假说,尽管其他解释还需要进一步研究。这些发现还表明,早期治疗心理和行为问题可能会预防或延迟吸烟的开始。